Key facts
- This page summarizes Charles Greg Guyer's Form 4 filing for BIOMARIN PHARMACEUTICAL INC (BMRN).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 Mar 2026, 20:50.
Charles Greg Guyer - 13 Mar 2026 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)
- Reporting relationship
- EVP, Chief Technical Officer
- Issuer ticker
- BMRN
- Reported as of
- 13 Mar 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Mar 2026, 20:50:38 UTC
- Prior SEC filing
- 12 Mar 2026
- Next SEC filing
- 19 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tae Sang Yoo, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Charles Greg Guyer filed Form 4 for BIOMARIN PHARMACEUTICAL INC (BMRN) on 17 Mar 2026.
Change
- Previous filing in this sequence was filed on 12 Mar 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001811096
Primary reporting owner
Guyer Charles Greg
- Relationship
- EVP, Chief Technical Officer
- Address
- C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO STREET, SAN RAFAEL
- Signature
- /s/ Tae Sang Yoo, Attorney-in-Fact
- Signature date
- 17 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BMRN
transaction
Common Stock
Tax liability
- Transaction value
- Shares
- -9,109
- Change %
- -11%
- Price
- $58.51*
- Shares after
- 70,843
- Date
- 13 Mar 2026
- Ownership
- Direct
BMRN
transaction
Common Stock
Award
- Transaction value
- Shares
- +14,990
- Change %
- +21%
- Price
- $0.000000*
- Shares after
- 85,833
- Date
- 16 Mar 2026
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BMRN
transaction
Derivative
Stock Option (Right to Buy Common Stock)
Award
- Transaction value
- Shares
- +35,680
- Change %
- Price
- $0.000000*
- Shares after
- 35,680
- Date
- 16 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,680
- Exercise price
- $57.43
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Restricted stock units granted March 16, 2026. Price not applicable.
Footnote F2
The Reporting Person's direct holdings have been adjusted by one share to correct a previous clerical error.
Footnote F3
Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter.